<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0405233589
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2023
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Tukysa
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        TUCATINIB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        88
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        9638.40
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Corden Pharma GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Corden Pharma GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Pfizer Europe MA EEIG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; What TUKYSA is</p><p>TUKYSA is a medicine for breast cancer. It contains the active substance tucatinib and it belongs to a group of medicines called protein kinase inhibitors which prevent the growth of some types of cancer cells in the body.</p><p>&nbsp;</p><p>What TUKYSA is used for</p><p>TUKYSA is used for adults who have breast cancer which:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has a receptor (target) on the cancer cells called human epidermal growth factor receptor 2 (HER2-positive breast cancer)</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has spread beyond the original tumour or to other organs such as the brain or cannot be removed by surgery</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; has previously been treated with certain other breast cancer treatments</p><p>&nbsp;</p><p>TUKYSA is taken with two other cancer medicines, <strong>trastuzumab </strong>and <strong>capecitabine</strong>. Separate patient information leaflets are available for these medicines. <strong>Ask your doctor </strong>to tell you about them.</p><p>&nbsp;</p><p>How TUKYSA works</p><p>TUKYSA works by blocking the HER2 receptors on cancer cells. HER2 produces signals that can help the cancer to grow, and blocking it may slow or stop cancer cells from growing or may kill them altogether.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take TUKYSA</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to tucatinib or any of the other ingredients of this medicine (listed in section&nbsp;6)</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talk to your doctor before taking TUKYSA if you have liver problems. During your treatment, your doctor will run tests to check that your liver is working properly.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TUKYSA can cause severe diarrhoea. Talk to your doctor right away at the first sign of diarrhoea (loose stool) and if your diarrhoea persists with nausea and/or vomiting.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TUKYSA may cause harm to an unborn baby when taken by a pregnant woman. Talk to your doctor before you take TUKYSA if you think you may be pregnant or are planning to have a baby. See section on &ldquo;Pregnancy and breast-feeding&rdquo; below.</p><p><strong>&nbsp;</strong></p><p><strong>Children and adolescents</strong></p><p>TUKYSA should not be used in children under the age of 18&nbsp;years. The safety of TUKYSA and how effective it is has not been studied in this age group.</p><p>&nbsp;</p><p>Other medicines and TUKYSA<!--[if supportFields]><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_e33b13c3-5dec-4b18-a2ea-74798969d61d \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=EN-GB style='font-size:11.0pt;font-family:"Times New Roman",serif'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><strong>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines</strong>.</p><p>&nbsp;</p><p>Some medicines may affect the way TUKYSA works or TUKYSA may affect the way they work. These medicines include some medicines in the following groups:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; St John&rsquo;s wort &ndash; a herbal product used to treat depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itraconazole, ketoconazole, voriconazole, posaconazole &ndash; used to treat fungal infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rifampicin &ndash; used to treat bacterial infections</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; darunavir, saquinavir, tipranavir &ndash; used to treat HIV</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; phenytoin, carbamazepine &ndash; used to treat epilepsy or a painful condition of the face called trigeminal neuralgia or to control serious mood disorder when other medicines do not work</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; buspirone&ndash; used to treat certain mental health problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sirolimus, tacrolimus &ndash; used to control your body&rsquo;s immune response after a transplant</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; digoxin &ndash; used to treat heart problems</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lomitapide, lovastatin &ndash; used to treat abnormal cholesterol levels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; alfentanil &ndash; used for pain relief</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; avanafil, vardenafil &ndash; used to treat erectile dysfunction</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; darifenacin &ndash; used to treat urinary incontinence</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; midazolam, triazolam &ndash;used to treat seizures, anxiety disorders, panic, agitation, and insomnia</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; repaglinide &ndash; used to treat type 2 diabetes</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ebastine &ndash; an antihistamine used to treat seasonal and perennial allergic rhinitis and rhino‑conjunctivitis.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; everolimus, ibrutinib &ndash; used to treat certain cancers</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; naloxegol &ndash; used to treat to treat constipation</p><p><strong>&nbsp;</strong></p><p><strong>Pregnancy and breast-feeding</strong></p><p>TUKYSA may cause harmful effects to an unborn baby when taken by a pregnant woman. Your doctor will do a pregnancy test before you start taking TUKYSA.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are<strong> pregnant</strong>, think you <strong>may be pregnant</strong> or are <strong>planning to have a baby</strong>, <strong>ask your doctor</strong> for advice before taking this medicine. The doctor will weigh the potential benefit to you against the risk to the unborn baby.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Use a reliable method of contraception</strong> to avoid becoming pregnant while you are taking TUKYSA and for at least 1&nbsp;week after the last dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>If you are male </strong><strong>and have a female sexual partner who can become pregnant, use a reliable method of contraception</strong> to avoid pregnancy while you are taking TUKYSA and for at least 1&nbsp;week after the last dose.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you <strong>become pregnant</strong> during treatment with TUKYSA, <strong>tell your doctor</strong>. The doctor will assess the potential benefit to you of continuing this medicine and the risk to the unborn baby.</p><p>&nbsp;</p><p>It is not known whether TUKYSA passes into breast milk.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are <strong>breast feeding</strong> or <strong>planning to breast feed</strong>, <strong>ask your doctor </strong>for advice before taking this medicine. You should not breastfeed during treatment with TUKYSA and for at least 1&nbsp;week after the last dose. Talk to your doctor about the best way to feed your baby during treatment.</p><p>&nbsp;</p><p><strong>Ask your doctor or pharmacist</strong> for advice before taking TUKYSA if you have any questions.</p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong></p><p>TUKYSA is not expected to affect your ability to drive or operate machines. However, you are responsible for deciding whether you can drive a motor vehicle or perform other tasks that require increased concentration.</p><p>&nbsp;</p><p><strong>TUKYSA contains sodium and potassium</strong></p><p>This medicine contains 55.3&nbsp;mg sodium (main component of cooking/table salt) in each 300 mg dose. This is equivalent to 2.75% of the recommended maximum daily dietary intake of sodium for an adult.</p><p>&nbsp;</p><p>This medicine contains 60.6 mg potassium per 300&nbsp;mg dose. To be taken into consideration by patients with reduced kidney function or patients on a controlled potassium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>Dosage</p><p>The recommended dose is 300 mg (two 150 mg tablets) by mouth twice a day.</p><p>&nbsp;</p><p>Your doctor may change your dose of TUKYSA if you experience certain side effects. To allow for a lower dose, your doctor may prescribe 50 mg tablets.</p><p>&nbsp;</p><p>Method of administration</p><p>TUKYSA can be taken with food or between meals.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swallow the tablets whole, one after the other.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Take each dose about 12 hours apart at the same times every day.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not chew or crush the tablet.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Do not take an additional dose if you vomit after taking TUKYSA but continue with the next scheduled dose.</p><p>&nbsp;</p><p>If you take more TUKYSA than you should</p><p>Talk to a doctor or pharmacist straight away. If possible, show them the pack.</p><p>&nbsp;</p><p>If you forget to take TUKYSA</p><p><strong>Do not take a double dose </strong>to make up for a forgotten dose. Just take the next dose at the scheduled time.</p><p>&nbsp;</p><p>&nbsp;</p><p>If you stop taking TUKYSA</p><p>TUKYSA is for long-term treatment and you should take it continuously. <strong>Do not stop taking TUKYSA</strong></p><p>without talking to your doctor.</p><p>&nbsp;</p><p>While you are taking TUKYSA</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Depending on the side effects you have, your doctor may recommend lowering your dose or temporarily stopping your treatment.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor will also check your liver function during treatment with TUKYSA.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may occur with this medicine.</p><p>&nbsp;</p><p><strong>Very common </strong>(may affect more than 1 in 10&nbsp;people):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling sick (nausea);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; being sick (vomiting);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; mouth sores, inflammation of the mouth, mouth ulcers;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; liver problems, which may cause itching, yellowing of eyes and skin, dark urine and pain or discomfort in the upper right area of the stomach;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; joint pain;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weight loss;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nosebleed</p><p>&nbsp;</p><p><strong>Tell your doctor or pharmacist </strong>if you notice any side effects.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system. By reporting side effects, you can help provide more information on the safety of this medicine.</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia: </strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>The National Pharmacovigilance Centre (NPC):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States: </strong></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the blister and the carton.</p><p>&nbsp;</p><p>Store below 30˚C</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What TUKYSA contains</strong></p><p>The <strong>active substance </strong>is tucatinib. Each film-coated tablet contains either 50 mg or 150 mg tucatinib.</p><p>The other ingredients are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tablet core - copovidone, crospovidone, sodium chloride, potassium chloride, sodium hydrogen carbonate, silica, colloidal anhydrous, magnesium stearate, microcrystalline cellulose (see section 2 &ldquo;TUKYSA contains sodium and potassium&rdquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Film-coating &ndash; poly (vinyl alcohol), titanium dioxide, macrogol, talc, yellow iron oxide.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                TUKYSA 50 mg film coated tablets (tablets) are round, yellow and debossed with “TUC” on one side and “50” on the reverse side. 
TUKYSA 150 mg film coated tablets (tablets) are oval shaped, yellow, and debossed with “TUC” on one side and “150” on the reverse side. 

TUKYSA is supplied in aluminium foil blisters. Each pack contains: 
TUKYSA 50 mg film coated tablets 
•	88 tablets. 
TUKYSA 150 mg film coated tablets 
•	84 tablets





TUKYSA is supplied in aluminium foil blisters. Each pack contains: TUKYSA 50 mg film-coated tablets

·                88 tablets (11 blisters of 8 tablets each). TUKYSA 150 mg film-coated tablets

·                84 tablets (21 blisters of 4 tablets each).

Not all pack sizes may be marketed.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder</strong><strong> </strong></p><p>Pfizer Europe MA EEIG</p><p>Belgium</p><p>&nbsp;</p><p><strong>Manufactured</strong><strong> by:</strong></p><p>Corden Pharma GmbH</p><p>Plankstadt, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                July 2023
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>ما توكيسا&nbsp; </strong></p><p dir="RTL">توكيسا هو دواء لسرطان الثدي. يحتوي توكيسا على المادة الفعالة توكاتينيب التي تنتمي إلى مجموعة من الأدوية تسمى مثبطات كيناز البروتين التي تمنع نمو بعض أنواع الخلايا السرطانية في الجسم.</p><p dir="RTL"><strong>ما دواعي استخدام توكيسا&nbsp; </strong></p><p dir="RTL">يُستخدم توكيسا&nbsp; للبالغين المُصابين بسرطان الثدي:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المتميز بوجود مُستقبل على الخلايا السرطانية يُسمى مُستقبل عامل النمو البشروي البشري الثاني (HER2&nbsp;receptor) )سرطان الثدي الإيجابي لعامل النمو البشروي البشري الثاني)</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المنتشر خارج الورم الأصلي أو إلى أعضاء أخرى مثل الدماغ أو لا يمكن إزالته عن طريق الجراحة</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذي قد سبق علاجه ببعض العلاجات الأخرى لسرطان الثدي</p><p dir="RTL">يتم تناول توكيسا&nbsp; مع إثنين آخرين من أدوية السرطان هما تراستوزوماب وكابيسايتابين. تتوفر لهذه الأدوية نشرات معلومات منفصلة للمريض. اطلب من طبيبك أن يخبرك عنهم.</p><p dir="RTL"><strong>كيف يعمل توكيسا&nbsp; </strong></p><p dir="RTL">توكيسا&nbsp; يعمل عن طريق منع مُستقبلات عامل النمو البشروي البشري الثاني (HER2&nbsp;receptors) الموجودة على الخلايا السرطانية. يقوم عامل النمو البشروي البشري الثاني (HER2) بإنتاج إشارات يمكن أن تساعد السرطان على النمو، وبالتالي قد يؤدي منعه إلى إبطاء نمو الخلايا السرطانية أو إيقافها أو قد يقتلها تمامًا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>موانع استعمال توكيسا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية من توكاتينيب أو أي من المكونات الأخرى لهذا الدواء (المدرجة في الفقرة رقم ٦).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الاحتياطات</strong><strong> عند استعمال توكيسا</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تواجه مشاكل في الكبد فتحدث إلى طبيبك قبل تناول توكيسا. خلال فترة العلاج، سيقوم طبيبك بإجراء اختبارات للتأكد من أنّ الكبد يعمل بشكل صحيح.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكن أن يُسبّب توكيسا الإسهال الحاد. تحدث إلى طبيبك على الفور عند أول علامة على الإسهال (البراز اللين) وإذا استمر الإسهال مصحوبًا بالغثيان و/أو القيء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يسبب توكيسا ضررًا للجنين عندما تأخذه المرأة الحامل. إذا كنتِ تعتقدين أنكِ حاملًا أو تخططين لإنجاب طفل فتحدثي إلى طبيبكِ قبل تناول توكيسا. انظري إلى الفقرة الخاصة بـ&nbsp;&quot;الحمل والرضاعة الطبيعية&quot; أدناه.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الأطفال والمراهقين</strong></p><p dir="RTL">لا ينبغي استخدام توكيسا في الأطفال دون سن ۱۸ عامًا. لم يتم دراسة مأمونية توكيسا ومدى فعاليته في هذه الفئة العمرية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>التداخلات الدوائية مع أخذ هذا المستحضر مع أي أدوية أخرى أو أعشاب أو مكملات غذائية </strong></p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي إذا كنت تتناول أدوية أخرى أو تناولتها مؤخرًا أو قد تتناولها</strong><strong>.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL">قد تؤثر بعض الأدوية على طريقة عمل توكيسا أو قد يؤثر توكيسا على طريقة عملها. تشمل هذه الأدوية بعض الأدوية في المجموعات التالية:</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نبتة سانت جون &ndash; منتج عشبي يستخدم لعلاج الاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إتراكونازول، كيتوكونازول، بوساكونازول، فوريكونازول - تستخدم لعلاج الالتهابات الفطرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريفامبسين &ndash; يستخدم لعلاج الالتهابات البكتيرية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دارونافير، ساكينافير، تيبيرانافير &ndash; تستخدم لعلاج فيروس نقص المناعة البشري</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فينيتوين، كاربامازبين &ndash; يستخدمانِ لعلاج الصرع أو لعلاج حالة مؤلمة في الوجه تسمى ألم العصب ثلاثي التوائم أو للسيطرة على اضطراب المزاج الخطير عندما لا تعمل الأدوية الأخرى</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بوسبيرون &ndash; يستخدم لعلاج بعض مشاكل الصحة العقلية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيروليموس، تاكروليموس &ndash; يستخدمانِ للسيطرة على استجابة الجسم المناعية بعد إجراء عملية زراعة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديجوكسين &ndash; يستخدم لعلاج مشاكل في القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لوميتابايد، لوفاستاتين &ndash; يستخدمان لعلاج مستويات الكولسترول غير الطبيعية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألفينتانيل &ndash; يستخدم لتخفيف الألم</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أفانافيل، فاردينافيل &ndash; يستخدمان لعلاج ضعف الانتصاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داريفيناسين &ndash; يستخدم لعلاج سلس البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميدازولام، ترايازولام &ndash; يستخدمان لمعالجة النوبات، اضطرابات القلق، الذعر، الاهتياج، والأرق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ريباجلينايد &ndash; يستخدم لعلاج مرض السكري النوع الثاني</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيباستاين &ndash; مضاد للهيستامين يستخدم لعلاج التهاب الأنف التحسسي الموسمي والمُزمن والتهاب الأنف والملتحمة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إيفروليماس، إيبروتينِب &ndash; يستخدمان لعلاج بعض أنواع السرطان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نالوكسغول &ndash; يستخدم لعلاج الإمساك</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الحمل والرضاعة </strong></p><p dir="RTL">توكيسا قد يسبب أعراضًا ضارة للجنين عندما يؤخذ من قبل امرأة حامل. سيقوم طبيبكِ بإجراء اختبار الحمل قبل البدء في تناول توكيسا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ <strong>حاملًا</strong> أو تعتقدين أنكِ <strong>قد تكونين حاملًا</strong> أو <strong>تخططين لإنجاب طفل</strong> فاستشيري طبيبكِ قبل تناول هذا الدواء. سيقوم الطبيب بتقييم الفائدة المحتملة لكِ مقابل الخطر على الجنين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; استخدمي <strong>وسيلة موثوقة لمنع الحمل</strong> لتجنب الحمل أثناء تناولكِ توكيسا ولمدة أسبوع واحد على الأقل بعد الجرعة الأخيرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنتَ ذَكَرًا ولديكَ شريك جنسي أنثى يمكن أن تُصبح حاملًا ، فاستخدم طريقة موثوقة لمنع الحمل</strong> لتجنب الحمل أثناء تناولك توكيسا ولمدة أسبوع&nbsp;واحد على الأقل بعد الجرعة الأخيرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا <strong>حصل الحمل</strong> أثناء العلاج توكيسا فأبلغي طبيبكِ. سيقوم الطبيب بتقييم الفائدة المحتملة لكِ من مواصلة هذا الدواء مقابل الخطر على الجنين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">من غير المعروف ما إذا كان توكيسا يتم إفرازه في حليب الثدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنتِ<strong> ترضعين رضاعةً طبيعيةً</strong><strong> </strong>أو <strong>تخططين للرضاعة الطبيعية</strong> <strong>فاستشيري طبيبكِ</strong> قبل تناول هذا الدواء. يجب عدم الإرضاع طبيعيا أثناء العلاج توكيسا و لمدة أسبوع واحد على الأقل بعد الجرعة الأخيرة. تحدثي مع طبيبكِ حول أفضل طريقة لإرضاع طفلكِ أثناء العلاج.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كان لديكِ أي أسئلة<strong> فاستشيري طبيبكِ</strong> <strong>أو الصيدلي </strong>قبل تناول توكيسا .</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تأثير توكيسا على القيادة واستخدام الآلات</strong></p><p dir="RTL">لا يتوقع أن يؤثر توكيسا على قدرتك على القيادة أو تشغيل الآلات. ومع ذلك ، فأنت مسؤول عن تحديد ما إذا كان بإمكانك قيادة السيارة أو أداء مهام أخرى تتطلب تركيزًا متزايدا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>معلومات هامة حول بعض مكونات توكيسا</strong></p><p dir="RTL"><strong>يحتوي توكيسا</strong> <strong>على الصوديوم والبوتاسيوم</strong></p><p dir="RTL">يحتوي هذا الدواء على ٥٥,۳ ملجم صوديوم (المكون الرئيسي للطهي/ملح الطعام) في كل جرعة مقدارها ۳۰۰&nbsp;ملجم. وهذا يعادل ۲,۷٥٪ من الحد الأقصى الموصى به من الحصة الغذائية اليومية للصوديوم للشخص البالغ.</p><p dir="RTL">&nbsp;</p><p dir="RTL">هذا الدواء يحتوي على ٦۰,٦ ملجم بوتاسيوم لكل جرعة مقدارها ۳۰۰&nbsp;ملجم يجب أن يؤخذ ذلك في الاعتبار من قبل المرضى الذين يعانون من قصور في وظائف الكِلى أو المرضى الذين يتبعون حمية غذائية للبوتاسيوم.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائمًا حسب ارشادات الطبيب أو الصيدلي تمامًا. تحقّق من طبيبك أو الصيدلي إذا لم تكن متأكدًا.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL">الجرعة الموصى بها هي 300&nbsp;ملغم (قرصين من تركيز 150&nbsp;ملغم) عن طريق الفم مرتين في اليوم.</p><p dir="RTL">قد يغير طبيبك جرعتك من توكيسا إذا واجهت بعض الأعراض الجانبية. وللحصول على جرعة أقل فقد يصف طبيبك أقراص تركيز 50&nbsp;ملغم.</p><p dir="RTL"><strong>طريقة الاستخدام</strong></p><p dir="RTL">يمكن تناول توكيسا&nbsp; مع الطعام أو بين الوجبات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ابلع الأقراص كاملة، واحدا تلو الآخر.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تناول كل جرعة بفاصل حوالي 12 ساعة عن الأخرى في نفس الأوقات من كل يوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تمضغ أو تسحق القرص.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لا تأخذ جرعة إضافية إذا تقيأت بعد تناول توكيسا ولكن واصل مع الجرعة التالية في وقتها المحدد.</p><p dir="RTL"><strong>إذا كنت تتناول توكيسا&nbsp; أكثر مما يجب</strong></p><p dir="RTL">تحدث إلى طبيب أو صيدلي على الفور. وإذا أمكن أظهر لهم العبوّة.</p><p dir="RTL"><strong>إذا نسيت أن تتناول توكيسا&nbsp; </strong></p><p dir="RTL"><strong>لا تأخذ جرعة مزدوجة </strong>للتعويض عن جرعة منسية. فقط خذ الجرعة التالية في وقتها المحدد.</p><p dir="RTL"><strong>إذا توقفت عن تناول توكيسا&nbsp; </strong></p><p dir="RTL">توكاسا مُخصّص للعلاج طويل الأمد، ويجب أن تتناوله بشكل مستمر. <strong>لا تتوقف عن تناول توكيسا&nbsp; </strong>دون التحدّث إلى طبيبك.</p><p dir="RTL"><strong>أثناء تناولك توكيسا&nbsp; </strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يوصي طبيبك بخفض الجرعة أو إيقاف العلاج مؤقتًا، وذلك حسب الأعراض الجانبية التي تعاني منها.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيقوم طبيبك أيضا بفحص وظائف الكبد أثناء العلاج باستخدام توكيسا&nbsp; .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&nbsp;</p><p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء أعراضًا جانبية، ومع ذلك فإنها لا تحدث لدى الجميع. الأعراض الجانبية التالية قد تحدث مع هذا الدواء.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة جدًّا </strong>(قد يؤثر على أكثر من ۱ من كل ۱۰ أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال ؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالمرض (غثيان) ؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قي ء؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرّحات في الفم، التهاب الفم، قرحة فموية ؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الكبد، والتي قد تسبب حكة ، اصفرار العينين والجلد ، بول داكن وألم أو انزعاج في الجزء العلوي الأيمن من المعدة ؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي ؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المفاصل ؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الوزن ؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رعاف (نزيف الأنف) .</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أخبر طبيبك أو الصيدلي </strong>إذا لاحظت أيّ أعراض جانبية.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الأعراض الجانبية</strong></p><p dir="RTL">إذا عانيت من أي أعراض جانبية فتحدث إلى طبيبك أو الصيدلي. وهذا يشمل أي أعراض جانبية محتملة غير مُدرجة في هذه النشرة. يمكنك أيضًا الإبلاغ عن الأعراض الجانبية مباشرةً عبر نظام الإبلاغ الوطني. بالإبلاغ عن الأعراض الجانبية يمكنك المساعدة في توفير المزيد من المعلومات حول مأمونيّة هذا الدواء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المملكة العربية السعودية</strong><strong>:</strong></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>المركز الوطني للتيقظ والسلامة الدوائية</strong><strong>:</strong></p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مركز الاتصال بالهيئة الهيئة العامة للغذاء والدواء: ۱۹۹۹۹</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البريد الإلكتروني: npc.drug@sfda.gov.sa</p><p dir="RTL">o&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الموقع الإلكتروني: https://ade.sfda.gov.sa/</p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>دول الخليج الأخرى:</strong></p><p dir="RTL"><u>&nbsp;</u></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الرجاء الاتصال بالسلطة المختصة المعنية.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ بعيدًا عن متناول أيدي ومرأى الأطفال</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على الشريط والكرتون الخاص به.</p><p dir="RTL">يُحفظ في درجة حرارة أقل من ٣۰ درجة مئوية</p><p dir="RTL">لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه التدابير على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>محتويات توكيسا&nbsp; </strong></p><p dir="RTL"><strong>المادة الفعالة </strong>هي توكاتينِب<strong>. </strong>يحتوي كل قرص مغلف بغشاء رقيق إمَّا على 50&nbsp;ملغم أو 150&nbsp;ملغم توكاتينيب.</p><p dir="RTL">المكونات الأخرى هي :</p><p dir="RTL">الأقراص : كوبوفيدون، كروسبوفيدون، كلوريد الصوديوم، كلوريد البوتاسيوم، بيكربونات الصوديوم، سيليكا غروية لا مائية، ستيرات المغنيسيوم، سليلوز دقيق التبلور (انظر الفقرة رقم 2 &quot;يحتوي توكيسا على الصوديوم والبوتاسيوم&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغلاف: كحول عديد الفينيل، ثاني أكسيد التيتانيوم، ماكروغول، تالك، أكسيد الحديد الأصفر.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص توكيسا ٥۰&nbsp;ملجم أقراص مُغلفة (أقراص) مستديرة الشكل صفراء اللّون ومحفور &quot;TUC&quot; على جانب و&nbsp;&quot;50&quot; على الجانب الآخر.</p><p dir="RTL">أقراص توكيسا ۱٥۰&nbsp;ملجم أقراص مُغلفة (أقراص) بيضاوية الشكل صفراء اللّون ومحفور &quot;TUC&quot; على جانب و&nbsp;&quot;150&quot; على الجانب الآخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يتوفر توكيسا في شرائط من رقائق الألومنيوم. تحتوي كل عبوة على:</p><p dir="RTL">توكيسا ٥۰&nbsp;ملجم أقراص مُغلفة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ۸۸ قرصًا.</p><p dir="RTL">توكيسا ۱٥۰&nbsp;ملجم أقراص مُغلفة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ۸٤ قرصًا.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المالكة لحقوق التسويق:</strong></p><p dir="RTL">فایزر یوروب إم أي إي إي جي، بلجیكا</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الشركة </strong><strong>الصانعة:</strong></p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كوردن فارما جي إم بي إتش</p><p dir="RTL">بلانكشتات،<strong> </strong>ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو 2023

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                
TUKYSA 50 mg film-coated tablets 
TUKYSA 150 mg film-coated tablets


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TUKYSA 50 mg film-coated tablets
Each film-coated tablet contains 50 mg of tucatinib.

TUKYSA 150 mg film-coated tablets
Each film-coated tablet contains 150 mg of tucatinib.

Excipients with known effect
Each 150 mg film-coated tablet contains 27.64 mg of sodium and 30.29 mg of potassium. A 300 mg dose of TUKYSA contains 55.3 mg of sodium and 60.6 mg of potassium.

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet.

TUKYSA 50 mg film-coated tablets

Round, yellow, film-coated tablet, debossed with “TUC” on one side and “50” on the other side. The 50 mg tablet has a diameter of approximately 8 mm.

TUKYSA 150 mg film-coated tablets

Oval-shaped, yellow, film-coated tablet, debossed with “TUC” on one side and “150” on the other side. The 150 mg tablet is approximately 17 mm in length and 7 mm in width.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TUKYSA is indicated in combination with trastuzumab and capecitabine for the treatment of adult patients with HER2‑positive locally advanced or metastatic breast cancer who have received at least 2 prior anti‑HER2 treatment regimens.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment with TUKYSA should be initiated and supervised by a physician experienced in the administration of anti&ndash;cancer medicinal products.</p><p>&nbsp;</p><p><u>Posology</u></p><p>&nbsp;</p><p>The recommended dose is 300&nbsp;mg tucatinib (two 150&nbsp;mg tablets) taken twice daily continuously in combination with trastuzumab and capecitabine, at doses described in table&nbsp;1. Refer to the summary of product characteristics (SmPC) for co-administered trastuzumab and capecitabine for additional information. The treatment components can be administered in any order.</p><p>&nbsp;</p><p><strong>Table</strong>&nbsp;<strong>1: Recommended dosing</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:606px"><tbody><tr><td style="vertical-align:bottom"><p><strong>Treatment</strong></p></td><td style="vertical-align:bottom"><p><strong>Dose</strong></p></td><td style="vertical-align:bottom"><p><strong>Treatment days </strong></p></td><td style="vertical-align:bottom"><p><strong>Timing relative to food intake</strong></p></td></tr><tr><td><p>Tucatinib</p></td><td><p>300&nbsp;mg orally</p><p>twice daily</p></td><td><p>Continuously</p></td><td style="vertical-align:bottom"><p>With or without a meal</p></td></tr><tr><td><p>Capecitabine</p></td><td><p>1000&nbsp;mg/m<sup>2</sup> orally</p><p>twice daily</p></td><td><p>Days&nbsp;1 to 14 every 21&nbsp;days</p></td><td style="vertical-align:bottom"><p>Within 30&nbsp;minutes after a meal</p></td></tr><tr><td style="vertical-align:bottom"><p>Trastuzumab</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:bottom"><p>Intravenous dosing</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td style="vertical-align:bottom"><p>&nbsp;</p></td><td rowspan="4"><p>Not applicable</p></td></tr><tr><td style="vertical-align:bottom"><p>Initial dose</p></td><td style="vertical-align:bottom"><p>8&nbsp;mg/kg intravenously</p></td><td style="vertical-align:bottom"><p>Day&nbsp;1</p></td></tr><tr><td style="vertical-align:top"><p>Subsequent doses</p></td><td style="vertical-align:top"><p>6&nbsp;mg/kg intravenously</p></td><td style="vertical-align:top"><p>Every&nbsp;21&nbsp;days</p></td></tr><tr><td style="vertical-align:bottom"><p>OR</p><p>Subcutaneous dosing</p></td><td style="vertical-align:bottom"><p>&nbsp;</p><p>600&nbsp;mg subcutaneously</p></td><td style="vertical-align:bottom"><p>&nbsp;</p><p>Every&nbsp;21&nbsp;days</p></td></tr></tbody></table><p>&nbsp;</p><p>Treatment with TUKYSA should be continued until disease progression or unacceptable toxicity.</p><p><u>&nbsp;</u></p><p><em><u>Missed dose</u></em></p><p>In the case of a missed dose, the patient should take their next dose at the regularly scheduled time.</p><p><u>&nbsp;</u></p><p><em><u>Dose modification </u></em></p><p>The recommended tucatinib dose modifications for patients with adverse reactions (see section&nbsp;4.8) are provided in Tables&nbsp;2 and 3. Refer to the SmPC for co‑administered trastuzumab and capecitabine for dose modifications for toxicities suspected to be caused by those therapies.</p><p>&nbsp;</p><p><strong>Table</strong><strong>&nbsp;</strong><strong>2: Recommended </strong><strong>tucatinib</strong><strong> </strong><strong>d</strong><strong>ose </strong><strong>r</strong><strong>eductions for </strong><strong>a</strong><strong>dverse </strong><strong>r</strong><strong>eactions</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>Dose level</strong></p></td><td style="vertical-align:top"><p><strong>Tucatini</strong><strong>b</strong><strong> dose</strong></p></td></tr><tr><td style="vertical-align:top"><p>Recommended starting dose</p></td><td style="vertical-align:top"><p>300&nbsp;mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>First dose reduction</p></td><td style="vertical-align:top"><p>250&nbsp;mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Second dose reduction</p></td><td style="vertical-align:top"><p>200&nbsp;mg twice daily</p></td></tr><tr><td style="vertical-align:top"><p>Third dose reduction</p></td><td style="vertical-align:top"><p>150&nbsp;mg twice daily<sup>1</sup></p></td></tr></tbody></table><p>1. TUKYSA should be permanently discontinued in patients unable to tolerate 150 mg orally twice daily.</p><p><strong>&nbsp;</strong></p><p><strong>Table</strong><strong>&nbsp;</strong><strong>3: Recommended tucatinib dose modifications for adverse reactions</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:606px"><tbody><tr><td><p><strong>Adverse Reaction</strong></p></td><td><p><strong>Severity</strong><strong><sup>1</sup></strong></p></td><td><p><strong>Tucatinib dosage modification</strong></p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Grade&nbsp;1 and 2</p></td><td style="vertical-align:top"><p>No dose modification is required.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;3 without anti-diarrheal treatment</p></td><td style="vertical-align:top"><p>Initiate or intensify appropriate medical therapy. Interrupt tucatinib until recovery to &le;&nbsp;Grade&nbsp;1, then resume tucatinib at the same dose level.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;3 with anti-diarrheal treatment</p></td><td style="vertical-align:top"><p>Initiate or intensify appropriate medical therapy. Interrupt tucatinib until recovery to &le;&nbsp;Grade&nbsp;1, then resume tucatinib at the next lower dose level.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;4</p></td><td style="vertical-align:top"><p>Permanently discontinue tucatinib.</p></td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Increased ALT, AST or total bilirubin<sup>2</sup></p></td><td style="vertical-align:top"><p>Grade&nbsp;1 bilirubin (&gt; ULN to 1.5 x ULN)</p></td><td style="vertical-align:top"><p>No dose modification is required.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;2 bilirubin (&gt; 1.5 to 3 &times; ULN)</p></td><td style="vertical-align:top"><p>Interrupt tucatinib until recovery to &le; Grade 1, then resume tucatinib at the same dose level.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;3 ALT or AST (&gt; 5 to 20 &times; ULN)</p><p>OR</p><p>Grade&nbsp;3 bilirubin (&gt; 3 to 10 &times; ULN)</p></td><td style="vertical-align:top"><p>Interrupt tucatinib until recovery to &le;&nbsp;Grade&nbsp;1, then resume tucatinib at the next lower dose level.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;4 ALT or AST (&gt; 20 &times; ULN)</p><p>OR</p><p>Grade&nbsp;4 bilirubin (&gt; 10 &times; ULN)</p></td><td style="vertical-align:top"><p>Permanently discontinue tucatinib.</p></td></tr><tr><td style="vertical-align:top"><p>ALT or AST &gt;&nbsp;3 &times; ULN</p><p>AND</p><p>Bilirubin &gt;&nbsp;2 &times; ULN</p></td><td style="vertical-align:top"><p>Permanently discontinue tucatinib.</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Other adverse reactions</p></td><td style="vertical-align:top"><p>Grade&nbsp;1 and 2</p></td><td style="vertical-align:top"><p>No dose modification is required.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;3</p></td><td style="vertical-align:top"><p>Interrupt tucatinib until recovery to &le; Grade&nbsp;1, then resume tucatinib at the next lower dose level.</p></td></tr><tr><td style="vertical-align:top"><p>Grade&nbsp;4</p></td><td style="vertical-align:top"><p>Permanently discontinue tucatinib.</p></td></tr></tbody></table><p>1. Grades based on National Cancer Institute Common Terminology Criteria for Adverse Events Version&nbsp;4.03</p><p>2. Abbreviations: ULN = upper limit of normal; ALT = alanine aminotransferase; AST = aspartate aminotransferase</p><p>&nbsp;</p><p><em><u>Co-administration with CYP2C8 inhibitors</u></em></p><p>Concomitant use with strong CYP2C8 inhibitors should be avoided. If coadministration with a strong CYP2C8 inhibitor cannot be avoided, the starting tucatinib dose should be reduced to 100&nbsp;mg orally twice daily. After discontinuation of the strong CYP2C8 inhibitor for 3&nbsp;elimination half-lives, the tucatinib dose that was taken prior to initiating the inhibitor should be resumed (see section&nbsp;4.4 and section&nbsp;4.5). Monitoring for TUKYSA toxicity should be increased when administered with moderate CYP2C8 inhibitors.</p><p><u>&nbsp;</u></p><p><em><u>Special populations</u></em></p><p><em>&nbsp;</em></p><p><em>Elderly</em></p><p>No dose adjustment is required in patients aged &ge;&nbsp;65&nbsp;years (see section&nbsp;5.2). Tucatinib has not been investigated in patients above the age of 80&nbsp;years.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>No dose adjustment is required in patients with mild, moderate, or severe renal impairment (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>H</em><em>epatic </em><em>impairment</em></p><p>No dose adjustment is required in patients with mild or moderate hepatic impairment (see section&nbsp;5.2). For patients with severe hepatic impairment (Child-Pugh C), a reduced starting dose of 200&nbsp;mg orally twice daily is recommended.</p><p><u>&nbsp;</u></p><p><em>Paediatric population</em></p><p>The safety and efficacy of TUKYSA in paediatric patients have not been established. No data are available.</p><p>&nbsp;</p><p><u>Method of administration </u></p><p>&nbsp;</p><p>TUKYSA is for oral use. The tablets should be swallowed whole and should not be chewed, crushed, or split prior to swallowing (see section&nbsp;5.2).</p><p>&nbsp;</p><p>TUKYSA should be taken approximately 12&nbsp;hours apart, at the same time every day, with or without a meal. TUKYSA may be taken at the same time with capecitabine.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Laboratory Tests</u></p><p><u>&nbsp;</u></p><p><em>Increased</em><em> ALT, AST, and bilirubin</em></p><p>Increased ALT, AST, and bilirubin have been reported during treatment with tucatinib (see section&nbsp;4.8). ALT, AST, and total bilirubin should be monitored every three weeks or as clinically indicated. Based on the severity of the adverse reaction, treatment with tucatinib should be interrupted, then dose reduced or permanently discontinued (see section&nbsp;4.2).</p><p>&nbsp;</p><p><em>Increased creatinine without impaired renal function</em></p><p>Increase in serum creatinine (30% mean increase) has been observed due to inhibition of renal tubular transport of creatinine without affecting glomerular function (see section 4.8). Alternative markers such as BUN, cystatin C, or calculated GFR, which are not based on creatinine, may be considered to determine whether renal function is impaired.</p><p>&nbsp;</p><p><u>Diarrhoea</u></p><p>&nbsp;</p><p>Diarrhoea, including severe events such as dehydration, hypotension, acute kidney injury and death, has been reported during treatment with tucatinib (see section&nbsp;4.8). If diarrhoea occurs, antidiarrheals should be administered as clinically indicated. For Grade &ge;3 diarrhoea, treatment with tucatinib should be interrupted, then dose reduced or permanently discontinued (see section&nbsp;4.2). Prompt medical management should also be instituted in the event of persistence of concomitant Grade 2 diarrhoea with concomitant Grade &ge;2 nausea and/or vomiting. Diagnostic tests should be performed as clinically indicated to exclude infectious causes of Grade&nbsp;3 or 4 diarrhoea or diarrhoea of any grade with complicating features (dehydration, fever, neutropenia).</p><p>&nbsp;</p><p><u>Embryo-foetal toxicity</u></p><p>&nbsp;</p><p>Based on findings from animal studies and its mechanism of action, tucatinib may cause harmful effects to the foetus when administered to a pregnant woman. In animal reproduction studies, administration of tucatinib to pregnant rabbits during organogenesis caused foetal abnormalities in rabbits at maternal exposures similar to the clinical exposures at the recommended dose.</p><p>Pregnant women should be advised of the potential risk to a foetus. Women of childbearing potential should be advised to use effective contraception during and up to at least 1&nbsp;week after the last dose of treatment (see section&nbsp;4.6). Male patients with female partners of childbearing potential should also be advised to use an effective method of contraception during and up to at least 1&nbsp;week after the last dose of treatment.</p><p>&nbsp;</p><p><u>Sensitive CYP3A substrates</u></p><p><u>&nbsp;</u></p><p>Tucatinib is a strong CYP3A inhibitor. Thus, tucatinib has the potential to interact with medicinal products that are metabolised by CYP3A, which may lead to increased plasma concentrations of the other product (see section&nbsp;4.5). When tucatinib is co‑administered with other medicinal products, the SmPC for the other product should be consulted for the recommendations regarding co-administration with CYP3A inhibitors. Concomitant treatment of tucatinib with CYP3A substrates when minimal concentration changes may lead to serious or life&ndash;threatening adverse reactions should be avoided. If concomitant use is unavoidable, the CYP3A substrate dosage should be reduced in accordance with the concomitant medicinal product SmPC.</p><p>&nbsp;</p><p><u>P‑gp substrates</u></p><p><u>&nbsp;</u></p><p>Concomitant use of tucatinib with a P‑gp substrate increased the plasma concentrations of P‑gp substrate, which may increase the toxicity associated with a P‑gp substrate. Dose reduction of P‑gp substrates (including sensitive intestinal substrate such as dabigatran) should be considered in accordance with the concomitant medicine SmPC and P‑gp substrates should be administered with caution when minimal concentration changes may lead to serious or life‑threatening toxicities.</p><p>&nbsp;</p><p><u>Strong CYP3A/moderate CYP2C8 inducers</u></p><p><u>&nbsp;</u></p><p>Concomitant use of tucatinib with a strong CYP3A or moderate CYP2C8 inducer decreased tucatinib concentrations, which may reduce tucatinib activity. Concomitant use with a strong CYP3A inducer or moderate CYP2C8 inducer should be avoided.</p><p><u>&nbsp;</u></p><p><u>Strong/moderate CYP2C8 inhibitors</u></p><p><u>&nbsp;</u></p><p>Concomitant use of tucatinib with a strong CYP2C8 inhibitor increased tucatinib concentrations, which may increase the risk of tucatinib toxicity. Concomitant use with strong CYP2C8 inhibitors should be avoided (see section&nbsp;4.2).</p><p>There are no clinical data on the impact of concomitant use of moderate CYP2C8 inhibitors on tucatinib concentrations. Monitoring for tucatinib toxicity should be increased with moderate CYP2C8 inhibitors.</p><p>&nbsp;</p><p><u>Information about excipients</u></p><p><u>&nbsp;</u></p><p>This medicinal product contains 55.3&nbsp;mg sodium per 300&nbsp;mg dose. This is equivalent to 2.75% of the recommended maximum daily dietary intake of sodium for an adult.</p><p>&nbsp;</p><p>This medicinal product contains 60.6&nbsp;mg potassium per 300 mg dose. This should be taken into consideration for patients who have impaired kidney function or are on a controlled potassium diet (diet with low potassium content).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tucatinib is primarily metabolised by CYP2C8. Tucatinib is a metabolism-based inactivator of CYP3A and inhibits renal transporters of metformin and creatinine. Tucatinib is a substrate of P&ndash;gp.</p><p>&nbsp;</p><p><u>Effects of other medicinal products on tucatinib</u></p><p>&nbsp;</p><p><em>CYP3A/CYP2C8 inducers</em></p><p>A clinical drug interaction study found that co-administration of a single dose of 300 mg tucatinib with rifampicin (a strong CYP3A and moderate CYP2C8 inducer) resulted in a reduction in tucatinib concentrations (0.6-fold Cmax (90% CI: 0.5, 0.8) and 0.5-fold AUC (90% CI: 0.4, 0.6)).</p><p>Co-administration of tucatinib with strong CYP3A or moderate CYP2C8 inducers such as rifampicin, phenytoin, St. John&#39;s wort, or carbamazepine should be avoided as this may result in decreased activity of tucatinib (see section 4.4).</p><p>&nbsp;</p><p><em>CYP2C8 inhibitors</em></p><p>A clinical drug interaction study found that co-administration of a single dose of 300 mg tucatinib with gemfibrozil (a strong CYP2C8 inhibitor) resulted in an increase in tucatinib concentrations (1.6-fold Cmax (90% CI: 1.5, 1.8) and 3.0-fold AUC (90% CI: 2.7, 3.5)). Co-administration of tucatinib with strong CYP2C8 inhibitors such as gemfibrozil should be avoided as this may result in increased risk of tucatinib toxicity (see section 4.4).</p><p>&nbsp;</p><p><em>CYP3A inhibitors</em></p><p>A clinical drug interaction study found that co-administration of a single dose of 300 mg tucatinib with itraconazole (a strong CYP3A inhibitor) resulted in an increase in tucatinib concentrations (1.3-fold Cmax (90% CI: 1.2, 1.4) and 1.3-fold AUC (90% CI: 1.3, 1.4)). No dose adjustment is required.</p><p>&nbsp;</p><p><em>Proton pump inhibitors</em></p><p>Based on clinical drug interaction studies conducted with tucatinib, no drug interactions were observed when tucatinib is combined with omeprazole (a proton pump inhibitor). No dose adjustment is required.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Effects of tucatinib on other medicinal products</u></p><p>&nbsp;</p><p><em>CYP3A substrates</em></p><p>Tucatinib is a strong CYP3A inhibitor. A clinical drug interaction study found that co-administration of tucatinib with midazolam (a sensitive CYP3A substrate) resulted in an increase in midazolam concentrations (3.0-fold Cmax (90% CI: 2.6, 3.4) and 5.7-fold AUC (90% CI: 5.0, 6.5)).</p><p>Co-administration of tucatinib with sensitive CYP3A substrates such as alfentanil, avanafil, buspirone, darifenacin, darunavir, ebastine, everolimus, ibrutinib, lomitapide, lovastatin, midazolam, naloxegol, saquinavir, simvastatin, sirolimus, tacrolimus, tipranavir, triazolam, and vardenafil may increase their systemic exposures which may increase the toxicity associated with a CYP3A substrate. Concomitant use of tucatinib with CYP3A substrates, when minimal concentration changes may lead to serious or life-threatening toxicities, should be avoided. If concomitant use is unavoidable, the CYP3A substrate dosage should be decreased in accordance with the concomitant medicinal product SmPC.</p><p>&nbsp;</p><p><em>P-gp substrates</em></p><p>A clinical drug interaction study found that co-administration of tucatinib with digoxin (a sensitive</p><p>P-gp substrate) resulted in an increase in digoxin concentrations (2.4-fold Cmax (90% CI: 1.9, 2.9) and 1.5-fold AUC (90% CI: 1.3, 1.7)). Concomitant use of tucatinib with a P-gp substrate may increase the plasma concentrations of the P-gp substrate, which may increase the toxicity associated with the P-gp substrate. Dose reduction of P-gp substrates (including sensitive intestinal substrate such as dabigatran) should be considered in accordance with the concomitant medicine SmPC and P-gp substrates should be administered with caution when minimal concentration changes may lead to serious or life-threatening toxicities (see section 4.4).</p><p>&nbsp;</p><p><em>CYP2C8 substrates</em></p><p>A clinical drug interaction study found that co-administration of tucatinib with repaglinide (a CYP2C8 substrate) resulted in an increase in repaglinide concentrations (1.7-fold Cmax (90% CI: 1.4, 2.1) and 1.7-fold AUC (90% CI: 1.5, 1.9)). No dose adjustment is required.</p><p>&nbsp;</p><p><em>MATE1/2K substrates</em></p><p>A clinical drug interaction study found that co-administration of tucatinib with metformin (a MATE1/2-K substrate) resulted in an increase in metformin concentrations (1.1-fold Cmax (90% CI: 1.0, 1.2) and 1.4-fold AUC (90% CI: 1.2, 1.5)). Tucatinib reduced the renal clearance of metformin without any effect on glomerular filtration rate (GFR) as measured by iohexol clearance and serum cystatin C. No dose adjustment is required.</p><p>&nbsp;</p><p><em>CYP2C9 substrates</em></p><p>Based on clinical drug interaction studies conducted with tucatinib, no drug interactions were observed when tucatinib is combined with tolbutamide (a sensitive CYP2C9 substrate). No dose adjustment is required.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Women of childbearing potential / Contraception in males and females</u></p><p>&nbsp;</p><p>Based on findings in animals, tucatinib may cause harmful pharmacological effects when administered to women during pregnancy and/or on the foetus/newborn child. Women of childbearing potential should be advised to avoid becoming pregnant and to use effective contraception during and up to at least 1 week after treatment. Male patients with female partners of childbearing potential should also be advised to use effective contraception during and up to at least 1 week after treatment (see section 4.4).</p><p>&nbsp;</p><p>Please also refer to section 4.6 of the prescribing information for trastuzumab and capecitabine. <u>Pregnancy</u></p><p>There are no data from the use of tucatinib in pregnant women. Studies in animals have shown reproductive toxicity (see section 5.3). TUKYSA should not be used during pregnancy unless the clinical condition of the woman requires treatment with tucatinib. The pregnancy status of women of childbearing potential should be verified prior to initiating treatment with tucatinib. If the patient becomes pregnant during treatment, the potential hazard to the foetus/newborn child must be explained to the patient.</p><p>&nbsp;</p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is unknown whether tucatinib/metabolites are excreted in human milk. A risk to the newborns/infants cannot be excluded. Breast-feeding should be discontinued during treatment with TUKYSA. Breast-feeding may be resumed 1 week after treatment.</p><p>&nbsp;</p><p><u>Fertility</u></p><p>&nbsp;</p><p>No fertility studies in men or women have been conducted. Based on findings from animal studies, tucatinib may impair fertility in females of reproductive potential (see section 5.3).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TUKYSA has no or negligible influence on the ability to drive and use machines. The clinical status of the patient should be considered when assessing the patient&rsquo;s ability to perform tasks that require judgment, motor, or cognitive skills.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>&nbsp;</p><p>The most commonly reported Grade&nbsp;3 and 4 adverse reactions (&ge;5%) during treatment are diarrhoea (13%), ALT increased (6%) and AST increased (5%).</p><p>Serious adverse reactions occurred in 29% of patients treated with tucatinib, and include diarrhoea (4%), vomiting (3%), and nausea (2%).</p><p>Adverse reactions leading to discontinuation of TUKYSA occurred in 6% of patients; the most common adverse reactions leading to discontinuation were diarrhoea (1%) and ALT increased (1%). Adverse reactions leading to dose reduction of TUKYSA occurred in 23% of patients; the most common adverse reactions leading to dose reduction were diarrhoea (6%), ALT increased (5%), and AST increased (4%).</p><p><u>&nbsp;</u></p><p><u>Tabulated list of adverse reactions</u></p><p><u>&nbsp;</u></p><p>The data summarised in this section reflect exposure to TUKYSA in 431&nbsp;patients with locally advanced unresectable or metastatic HER2-positive breast cancer who received TUKYSA in combination with trastuzumab and capecitabine across two studies, HER2CLIMB and ONT‑380‑005 (see section&nbsp;5.1). The median duration of exposure to TUKYSA across these studies was 7.4&nbsp;months (range, &lt;0.1, 43.6).</p><p>&nbsp;</p><p>The adverse reactions observed during treatment are listed in this section by frequency category. Frequency categories are defined as follows: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000); not known (cannot be estimated from the available data).</p><p><strong>Table&nbsp;</strong><strong>4</strong><strong>. Adverse reactions </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:612px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Respiratory, thoracic and mediastinal disorders</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Epistaxis</p></td></tr><tr><td style="vertical-align:top"><p><strong>Gastrointestinal disorders</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Diarrhoea, Nausea, Vomiting, Stomatitis<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Skin and subcutaneous tissue disorders</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Rash<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>Musculoskeletal and connective tissue disorders</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Arthralgia</p></td></tr><tr><td style="vertical-align:top"><p><strong>Investigations</strong></p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>AST increase, ALT increase, Blood bilirubin increased<sup>3</sup>, weight decrease</p></td></tr></tbody></table><p>1. Stomatitis includes stomatitis, oropharyngeal pain, mouth ulceration, oral pain, lip ulceration, glossodynia, tongue blistering, lip blister, oral dysaesthesia, tongue ulceration, aphthous ulcer</p><p>2. Rash includes rash maculo-papular, rash, dermatitis acneiform, erythema, rash macular, rash papular, rash pustular, rash pruritic, rash erythematous, skin exfoliation, urticaria, dermatitis allergic, palmar erythema, plantar erythema and skin toxicity</p><p>3. Blood bilirubin increased also includes hyperbilirubinemia</p><p>&nbsp;</p><p><u>Description of selected adverse reactions</u></p><p><strong><em>&nbsp;</em></strong></p><p><em>Increased ALT, AST, or bilirubin</em></p><p>In HER2CLIMB, increased ALT, AST or bilirubin occurred in 41% of patients treated with tucatinib in combination with trastuzumab and capecitabine. Grade&nbsp;3 and above events occurred in 9% of patients. Increased ALT, AST or bilirubin led to dose reduction in 9% of patients and treatment discontinuation in 1.5% of patients. The median time to onset of any grade increased ALT, AST, or bilirubin was 37&nbsp;days; 84% of events resolved, with a median time to resolution of 22&nbsp;days. Monitoring and dose modification (including discontinuation) should be considered (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Diarrhoea</em></p><p>In HER2CLIMB, diarrhoea occurred in 82% of patients treated with tucatinib in combination with trastuzumab and capecitabine. Grade&nbsp;3 and above diarrhoea events occurred in 13% of patients. Two patients who developed Grade 4 diarrhoea subsequently died, with diarrhoea as a contributor to death. Diarrhoea led to dose reduction in 6% of the patients and treatment discontinuation in 1% of the patients. The median time to onset of any grade diarrhoea was 12&nbsp;days; 81% of diarrhoea events resolved, with a median time to resolution of 8&nbsp;days. Prophylactic use of antidiarrheals was not required. Antidiarrheal medicinal products were used in less than half of the treatment cycles where diarrhoea events were reported. The median duration of antidiarrheal use was 3&nbsp;days per cycle (see section&nbsp;4.4).</p><p>&nbsp;</p><p><em>Increased creatinine without impaired renal function</em></p><p>Increase in serum creatinine has been observed in patients treated with tucatinib due to inhibition of renal tubular transport of creatinine without affecting glomerular function. In clinical studies, increases in serum creatinine (30% mean increase) occurred within the first cycle of tucatinib, remained elevated but stable throughout treatment and were reversible upon treatment discontinuation.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly</em></p><p>In the HER2CLIMB study, 82&nbsp;patients who received tucatinib were &ge;65&nbsp;years, of whom 8&nbsp;patients were &ge;75&nbsp;years. The incidence of serious adverse reactions was 34% in patients &ge; 65&nbsp;years compared to 28% in patients &lt; 65&nbsp;years. There were too few patients &ge;75&nbsp;years to assess differences in safety.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p><u>&nbsp;</u></p><p>Reporting suspected adverse reactions after marketing authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via National Pharmacovigilance Centre (NPC).</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia: </strong></p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>The National Pharmacovigilance Centre (NPC):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States: </strong></p><p><u>&nbsp;</u></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>Please contact the relevant competent authority.</em></p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no specific antidote, and the benefit of haemodialysis in the treatment of tucatinib overdose is unknown. In the event of an overdose, treatment with tucatinib should be withheld and general supportive measures should be applied.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antineoplastic agents, protein kinase inhibitors, ATC code: L01EH03.</p><p><strong>&nbsp;</strong></p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Tucatinib is a reversible, potent and selective tyrosine kinase inhibitor of HER2. In cellular signalling assays, tucatinib is &gt;1000‑fold more selective for HER2 compared to epidermal growth factor receptor. <em>In vitro</em>, tucatinib inhibits phosphorylation of HER2 and HER3, resulting in inhibition of downstream cell signalling and cell proliferation, and induces death in HER2 driven tumour cells. <em>In vivo</em>, tucatinib inhibits the growth of HER2 driven tumours and the combination of tucatinib and trastuzumab showed enhanced anti‑tumour activity <em>in vitro</em> and <em>in vivo</em> compared to either medicinal product alone.</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p><em>&nbsp;</em></p><p><em>Cardiac electrophysiology </em></p><p>Multiple doses of tucatinib 300&nbsp;mg twice a day did not have an effect on the QTc interval in a TQT study in healthy subjects.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>&nbsp;</p><p>The efficacy of tucatinib in combination with trastuzumab and capecitabine was evaluated in a randomised, double-blind, placebo-controlled, active comparator, global study (HER2CLIMB). Patients enrolled had locally advanced unresectable or metastatic HER2‑positive breast cancer, with or without brain metastases, and had prior treatment with trastuzumab, pertuzumab, and trastuzumab emtansine (T-DM1) separately or in combination, in the neoadjuvant, adjuvant or metastatic setting. HER2 overexpression or amplification was confirmed by central laboratory analysis.</p><p>Patients with brain metastases, including those with untreated or progressing lesions, were eligible to enrol provided they were neurologically stable and did not require immediate brain radiation or surgery. Patients who required immediate local intervention could receive local therapy and be subsequently enrolled. The study included patients with untreated brain metastases and patients with treated brain metastases that were either stable or progressing since last brain radiation or surgery. Patients were excluded from the study if they received systemic corticosteroids (&ge;2&nbsp;mg total daily of dexamethasone or equivalent) for control of symptoms of CNS metastases &lt;28&nbsp;days prior to the first dose of study treatment. The study also excluded patients with leptomeningeal disease. Patients who had previously been treated with HER2 tyrosine kinase inhibitors were excluded with the exception of patients who received lapatinib for &le;21&nbsp;days and was discontinued for reasons other than disease progression or severe toxicity. For patients with hormone receptor positive tumors, endocrine therapy was not permitted as concomitant therapy, with the exception of gonadotropin-releasing hormone agonists used for ovarian suppression in premenopausal women.</p><p>A total of 612&nbsp;patients were randomised 2:1 to receive tucatinib in combination with trastuzumab and capecitabine (N=410) or placebo in combination with trastuzumab and capecitabine (N=202). Randomisation was stratified by the presence or history of brain metastases (yes <em>vs.</em> no), Eastern Cooperative Oncology Group (ECOG) performance status (0 <em>vs.</em> 1), and region (U.S., Canada, or rest of world).</p><p>&nbsp;</p><p>Patient demographics were balanced between treatment arms. The median age was 54&nbsp;years (range,&nbsp;25&nbsp;to 82); 116 (19%) patients were aged 65&nbsp;years or older. 444&nbsp;patients were white (73%) and 607&nbsp;were female (99%). 314&nbsp;patients (51%) had an ECOG performance status of 1 and 298&nbsp;patients (49%) had an ECOG performance status of 0. Sixty percent had oestrogen and/or progesterone receptor-positive disease. Forty-eight percent of patients had a presence or history of brain metastases; of these, 23% had untreated brain metastases, 40% had treated but stable brain metastases, and 37% had treated but radiographically progressing brain metastases. Additionally, 49% of patients had lung metastases, 35% had liver metastases, and 14% had skin metastases. Patients had a median of 4 (range, 2 to 17) prior lines of systemic therapy and a median of 3 (range, 1 to 14) prior lines of systemic therapy in the metastatic setting. All patients received prior trastuzumab‑based treatments and trastuzumab emtansine, while all but two patients had prior pertuzumab‑based treatment.</p><p>&nbsp;</p><p>Tucatinib or placebo, 300&nbsp;mg orally twice per day, was administered until disease progression or unacceptable toxicity. Trastuzumab was administered intravenously as a loading dose of 8&nbsp;mg/kg on Day&nbsp;1 of Cycle&nbsp;1, followed by a maintenance dose of 6&nbsp;mg/kg on Day&nbsp;1 of each subsequent 21‑day cycle. An alternate dosing option for trastuzumab was a fixed dose of 600&nbsp;mg administered subcutaneously on Day&nbsp;1 of each 21-day cycle. Capecitabine, 1000&nbsp;mg/m<sup>2</sup> orally twice per day, was administered on Days&nbsp;1 through 14 of each 21‑day cycle.</p><p>&nbsp;</p><p>The primary endpoint was progression-free survival (PFS) by blinded independent central review (BICR) in the first 480&nbsp;randomized patients. In this population, the median duration of exposure to tucatinib was 7.3&nbsp;months (range &lt;0.1, 35.1) for patients on the tucatinib + trastuzumab + capecitabine arm compared to 4.4&nbsp;months (range &lt;0.1, 24.0) of placebo for patients on the placebo + trastuzumab + capecitabine arm. Similar differences in exposure to trastuzumab and capecitabine were observed.</p><p>Secondary endpoints were evaluated in all randomized patients (N=612) and included overall survival (OS), PFS among patients with a history or presence of brain metastases (PFS<sub>BrainMets</sub>) and confirmed objective response rate (ORR).</p><p>&nbsp;</p><p>Primary and key secondary endpoint results were consistent across pre-specified subgroups: hormone receptor status, presence or history of brain metastases, ECOG status, and region. PFS as determined by the investigator was consistent with PFS as assessed by BICR.</p><p>&nbsp;</p><p>Efficacy results from the primary analysis are summarized in Table&nbsp;5 and Figures 1 and 2.</p><p><strong>&nbsp;</strong></p><p><strong>Table </strong><strong>5. Efficacy results from the HER2CLIMB study (primary analysis)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:618px"><tbody><tr><td style="vertical-align:bottom"><p>&nbsp;</p></td><td colspan="2" style="vertical-align:bottom"><p><strong>Tucatinib</strong><strong> + Trastuzumab + Capecitabine</strong></p></td><td style="vertical-align:bottom"><p><strong>Placebo + Trastuzumab + Capecitabine</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS<sup>1</sup></strong></p></td><td colspan="2"><p><strong>N=320</strong></p></td><td><p><strong>N=160</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of events (%)</p></td><td colspan="2"><p>178 (56)</p></td><td><p>97 (61)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)<sup>2</sup></p></td><td colspan="3"><p>0.54 (0.42, 0.71)</p></td></tr><tr><td style="vertical-align:top"><p>P-value<sup>3</sup></p></td><td colspan="3"><p>&lt;0.00001</p></td></tr><tr><td style="vertical-align:top"><p>Median (months) (95% CI)</p></td><td><p>7.8 (7.5, 9.6)</p></td><td colspan="2"><p>5.6 (4.2, 7.1)</p></td></tr><tr><td style="vertical-align:top"><p><strong>OS </strong></p></td><td><p><strong>N=410</strong></p></td><td colspan="2"><p><strong>N=202</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of deaths, n (%)</p></td><td><p>130 (32)</p></td><td colspan="2"><p>85 (42)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)<sup>2</sup></p></td><td colspan="3"><p>0.66 (0.50, 0.87)</p></td></tr><tr><td style="vertical-align:top"><p>P-value<sup>3</sup></p></td><td colspan="3"><p>0.00480</p></td></tr><tr><td style="vertical-align:top"><p>Median OS, months (95% CI)</p></td><td><p>21.9 (18.3, 31.0)</p></td><td colspan="2"><p>17.4 (13.6, 19.9)</p></td></tr><tr><td style="vertical-align:top"><p><strong>PFS<sub>BrainMets</sub><sup>4</sup></strong></p></td><td><p><strong>N=198</strong></p></td><td colspan="2"><p><strong>N=93</strong></p></td></tr><tr><td style="vertical-align:top"><p>Number of events (%)</p></td><td style="vertical-align:top"><p>106 (53.5)</p></td><td colspan="2" style="vertical-align:top"><p>51 (54.8)</p></td></tr><tr><td style="vertical-align:top"><p>Hazard ratio (95% CI)<sup>2</sup></p></td><td colspan="3" style="vertical-align:top"><p>0.48 (0.34, 0.69)</p></td></tr><tr><td style="vertical-align:top"><p>P-value<sup>3</sup></p></td><td colspan="3" style="vertical-align:top"><p>&lt;0.00001</p></td></tr><tr><td style="vertical-align:top"><p>Median (months) (95% CI)</p></td><td style="vertical-align:top"><p>7.6 (6.2, 9.5)</p></td><td colspan="2" style="vertical-align:top"><p>5.4 (4.1, 5.7)</p></td></tr><tr><td style="vertical-align:top"><p><strong>Confirmed ORR for Patients with Measurable Disease</strong></p></td><td><p><strong>N=340</strong></p></td><td colspan="2"><p><strong>N=171</strong></p></td></tr><tr><td style="vertical-align:top"><p>ORR (95% CI)<sup>5</sup></p></td><td><p>40.6 (35.3, 46.0)</p></td><td colspan="2"><p>22.8 (16.7, 29.8)</p></td></tr><tr><td style="vertical-align:top"><p>P-value<sup>6 </sup></p></td><td colspan="3"><p>0.00008</p></td></tr><tr><td style="vertical-align:top"><p>CR (%)</p></td><td><p>3 (0.9)</p></td><td colspan="2"><p>2 (1.2)</p></td></tr><tr><td style="vertical-align:top"><p>PR (%)</p></td><td><p>135 (39.7)</p></td><td colspan="2"><p>37 (21.6)</p></td></tr><tr><td style="vertical-align:top"><p><strong>DOR</strong></p></td><td><p>&nbsp;</p></td><td colspan="2"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Median DOR in months (95% CI)<sup> 7</sup></p></td><td><p>8.3 (6.2, 9.7)</p></td><td colspan="2"><p>6.3 (5.8, 8.9)</p></td></tr><tr><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p>BICR=blinded independent central review; CI=confidence interval; PFS=progression-free survival; OS=overall survival; ORR=objective response rate; CR=complete response; PR=partial response; DOR=duration of response.</p><p>1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Primary PFS analysis conducted in first 480 randomized patients. PFS based on Kaplan-Meier analyses.</p><p>2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hazard ratio and 95% confidence intervals are based on stratified Cox proportional hazards regression model controlling for stratification factors (presence or history of brain metastases, Eastern Cooperative Oncology Group (ECOG) status, and region of world)</p><p>3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Two-sided p-value based on re-randomization procedure controlling for stratification factors</p><p>4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Analysis includes patients with history or presence of parenchymal brain metastases at baseline, including target and non-target lesions. Does not include patients with dural lesions only.</p><p>5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Two-sided 95% exact confidence interval, computed using the Clopper-Pearson method</p><p>6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cochran-Mantel-Haenszel test controlling for stratification factors (presence or history of brain metastases, Eastern Cooperative Oncology Group (ECOG) status, and region of world)</p><p>7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Calculated using the complementary log-log transformation method</p><p>&nbsp;</p><p><strong>Figure</strong><strong>&nbsp;1. Kaplan‑Meier curves of </strong><strong>progression-free survival (per BICR) </strong></p><p><!--[if gte vml 1]><o:wrapblock><v:group id="Group_x0020_2" o:spid="_x0000_s1038"
  style='position:absolute;margin-left:9.35pt;margin-top:34.2pt;width:445.8pt;
  height:268.25pt;z-index:251659264;mso-width-relative:margin;
  mso-height-relative:margin' coordorigin="777,-744" coordsize="61633,38492"
  o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
  <v:shapetype id="_x0000_t75" coordsize="21600,21600" o:spt="75"
   o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
   <v:stroke joinstyle="miter"/>
   <v:formulas>
    <v:f eqn="if lineDrawn pixelLineWidth 0"/>
    <v:f eqn="sum @0 1 0"/>
    <v:f eqn="sum 0 0 @1"/>
    <v:f eqn="prod @2 1 2"/>
    <v:f eqn="prod @3 21600 pixelWidth"/>
    <v:f eqn="prod @3 21600 pixelHeight"/>
    <v:f eqn="sum @0 0 1"/>
    <v:f eqn="prod @6 1 2"/>
    <v:f eqn="prod @7 21600 pixelWidth"/>
    <v:f eqn="sum @8 21600 0"/>
    <v:f eqn="prod @7 21600 pixelHeight"/>
    <v:f eqn="sum @10 21600 0"/>
   </v:formulas>
   <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
   <o:lock v:ext="edit" aspectratio="t"/>
  </v:shapetype><v:shape id="Picture_x0020_2" o:spid="_x0000_s1039" type="#_x0000_t75"
   alt="A close up of a logo&#10;&#10;Description automatically generated"
   style='position:absolute;left:6399;width:56011;height:36486;visibility:visible;
   mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQD1oxDjwwAAANoAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9BawIx
FITvBf9DeEJvNbsK2q5GKUVLPfSg7cHjY/PcrG5eliTrbv+9KRR6HGbmG2a1GWwjbuRD7VhBPslA
EJdO11wp+P7aPT2DCBFZY+OYFPxQgM169LDCQrueD3Q7xkokCIcCFZgY20LKUBqyGCauJU7e2XmL
MUlfSe2xT3DbyGmWzaXFmtOCwZbeDJXXY2cVzL3D4eXy3pxw339u87i4dGah1ON4eF2CiDTE//Bf
+0MrmMHvlXQD5PoOAAD//wMAUEsBAi0AFAAGAAgAAAAhANvh9svuAAAAhQEAABMAAAAAAAAAAAAA
AAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEAWvQsW78AAAAVAQAACwAA
AAAAAAAAAAAAAAAfAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEA9aMQ48MAAADaAAAADwAA
AAAAAAAAAAAAAAAHAgAAZHJzL2Rvd25yZXYueG1sUEsFBgAAAAADAAMAtwAAAPcCAAAAAA==
">
   <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/13/msohtmlclip1/01/clip_image001.png"
    o:title="A close up of a logo&#10;&#10;Description automatically generated"/>
  </v:shape><v:shapetype id="_x0000_t202" coordsize="21600,21600" o:spt="202"
   path="m,l,21600r21600,l21600,xe">
   <v:stroke joinstyle="miter"/>
   <v:path gradientshapeok="t" o:connecttype="rect"/>
  </v:shapetype><v:shape id="TextBox_x0020_3" o:spid="_x0000_s1040" type="#_x0000_t202"
   style='position:absolute;left:32663;top:17228;width:19018;height:2565;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-size:11.0pt;
      color:black;mso-themecolor:text1;mso-font-kerning:12.0pt'>TUC+Tras+Cape</span><span
      lang=EN-GB style='font-size:12.0pt'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="TextBox_x0020_4" o:spid="_x0000_s1041" type="#_x0000_t202"
   style='position:absolute;left:15538;top:22988;width:11100;height:2565;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-size:11.0pt;
      color:black;mso-themecolor:text1;mso-font-kerning:12.0pt'>Pbo+Tras+Cape</span><span
      lang=EN-GB style='font-size:12.0pt'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="TextBox_x0020_5" o:spid="_x0000_s1042" type="#_x0000_t202"
   style='position:absolute;left:28646;top:31285;width:23035;height:2565;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-size:11.0pt;
      color:black;mso-themecolor:text1;mso-font-kerning:12.0pt'>Months since
      randomisation</span><span lang=EN-GB style='font-size:12.0pt'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="TextBox_x0020_6" o:spid="_x0000_s1043" type="#_x0000_t202"
   style='position:absolute;left:-4254;top:9909;width:23732;height:2425;
   rotation:-90;visibility:visible;mso-wrap-style:square;v-text-anchor:top'
   o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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==
" filled="f" stroked="f">
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-size:11.0pt;
      color:black;mso-themecolor:text1;mso-font-kerning:12.0pt'>Progression
      free survival </span><span lang=EN-GB style='font-size:12.0pt'><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><v:shape id="TextBox_x0020_7" o:spid="_x0000_s1044" type="#_x0000_t202"
   style='position:absolute;left:777;top:30626;width:19018;height:7122;
   visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
   <v:textbox>
    <![if !mso]>
    <table cellpadding=0 cellspacing=0 width="100%">
     <tr>
      <td><![endif]>
      <div>
      <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-size:11.0pt;
      color:black;mso-themecolor:text1;mso-font-kerning:12.0pt'>Patients at
      risk</span><span lang=EN-GB style='font-size:12.0pt'><o:p></o:p></span></p>
      <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-size:11.0pt;
      color:black;mso-themecolor:text1;mso-font-kerning:12.0pt'>TUC+Tras+Cape</span><span
      lang=EN-GB><o:p></o:p></span></p>
      <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-size:11.0pt;
      color:black;mso-themecolor:text1;mso-font-kerning:12.0pt'>Pbo+Tras+Cape</span><span
      lang=EN-GB><o:p></o:p></span></p>
      </div>
      <![if !mso]></td>
     </tr>
    </table>
    <![endif]></v:textbox>
  </v:shape><w:wrap type="topAndBottom"/>
 </v:group><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td><img width="597" height="362" src="file:///C:/Users/bakhsm/AppData/Local/Temp/13/msohtmlclip1/01/clip_image002.png" /></td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>Figure 2. </strong><strong>Kaplan‑Meier curves of </strong><strong>progression-free survival (per BICR) in patients with brain metastases</strong><strong> </strong></p><p><!--[if mso & !supportInlineShapes & supportFields]><span lang=EN-GB><span
style='mso-element:field-begin;mso-field-lock:yes'></span><span
style='mso-spacerun:yes'> </span>SHAPE <span
style='mso-spacerun:yes'> </span>\* MERGEFORMAT <span style='mso-element:field-separator'></span></span><![endif]--><!--[if gte vml 1]><v:group id="Group_x0020_28" o:spid="_x0000_s1031"
 style='width:494.3pt;height:302.55pt;mso-position-horizontal-relative:char;
 mso-position-vertical-relative:line' coordsize="62777,38424" o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
 <v:shape id="Picture_x0020_8" o:spid="_x0000_s1032" type="#_x0000_t75" alt="A close up of a logo&#10;&#10;Description automatically generated"
  style='position:absolute;left:3964;width:58813;height:38303;visibility:visible;
  mso-wrap-style:square' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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">
  <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/13/msohtmlclip1/01/clip_image003.png"
   o:title="A close up of a logo&#10;&#10;Description automatically generated"/>
 </v:shape><v:shape id="TextBox_x0020_3" o:spid="_x0000_s1033" type="#_x0000_t202"
  style='position:absolute;left:42074;top:24953;width:19012;height:2565;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCbcZZpwQAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Ba8JA
FITvBf/D8gRvdWPAUlJXEa3gwUtten9kn9lg9m3Ivpr4712h0OMwM98wq83oW3WjPjaBDSzmGSji
KtiGawPl9+H1HVQUZIttYDJwpwib9eRlhYUNA3/R7Sy1ShCOBRpwIl2hdawceYzz0BEn7xJ6j5Jk
X2vb45DgvtV5lr1pjw2nBYcd7RxV1/OvNyBit4t7+enj8Wc87QeXVUssjZlNx+0HKKFR/sN/7aM1
kOfw/JJ+gF4/AAAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAAAAAA
AAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAAAA
AAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAJtxlmnBAAAA2wAAAA8AAAAA
AAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD1AgAAAAA=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-size:11.0pt;
     color:black;mso-themecolor:text1;mso-font-kerning:12.0pt'>TUC+Tras+Cape</span><span
     lang=EN-GB style='font-size:12.0pt'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="TextBox_x0020_4" o:spid="_x0000_s1034" type="#_x0000_t202"
  style='position:absolute;left:15802;top:25423;width:11100;height:2565;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-size:11.0pt;
     color:black;mso-themecolor:text1;mso-font-kerning:12.0pt'>Pbo+Tras+Cape</span><span
     lang=EN-GB style='font-size:12.0pt'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="TextBox_x0020_5" o:spid="_x0000_s1035" type="#_x0000_t202"
  style='position:absolute;left:26902;top:31446;width:19012;height:2566;
  visibility:visible;mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQB71KuGwgAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Pa8JA
FMTvBb/D8gq91Y3SiqSuIv4BD72o8f7IvmZDs29D9mnit3eFQo/DzPyGWawG36gbdbEObGAyzkAR
l8HWXBkozvv3OagoyBabwGTgThFWy9HLAnMbej7S7SSVShCOORpwIm2udSwdeYzj0BIn7yd0HiXJ
rtK2wz7BfaOnWTbTHmtOCw5b2jgqf09Xb0DErif3Yufj4TJ8b3uXlZ9YGPP2Oqy/QAkN8h/+ax+s
gekHPL+kH6CXDwAAAP//AwBQSwECLQAUAAYACAAAACEA2+H2y+4AAACFAQAAEwAAAAAAAAAAAAAA
AAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQBa9CxbvwAAABUBAAALAAAA
AAAAAAAAAAAAAB8BAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQB71KuGwgAAANsAAAAPAAAA
AAAAAAAAAAAAAAcCAABkcnMvZG93bnJldi54bWxQSwUGAAAAAAMAAwC3AAAA9gIAAAAA
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-size:11.0pt;
     color:black;mso-themecolor:text1;mso-font-kerning:12.0pt'>Months since randomisation</span><span
     lang=EN-GB style='font-size:12.0pt'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="TextBox_x0020_6" o:spid="_x0000_s1036" type="#_x0000_t202"
  style='position:absolute;left:-3051;top:14836;width:19990;height:2559;
  rotation:-90;visibility:visible;mso-wrap-style:square;v-text-anchor:top'
  o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH
70i8Q+QralM4IITa7kDhCAiNB7ASt43WOlEcyvb2pNu4IODoPz9/n1xv9vOkForiPDdwXVagiI23
jocG3rdPxR0oScgWJ8/UwIEENu3lRb09BBKV0ywNjCmFe63FjDSjlD4Q50nv44wpl3HQAc0OB9I3
VXWrjedEnIq03oC27qjHjympx31un0wiTQLq4bS4shrAECZnMGVTvbD9QSnOhDInjzsyuiBXWQP0
r4R18jfgnHvJr4nOknrFmJ5xzhraRtHWf3Kkpfz/yGo5S+H73hkquyhdjr3R8m2lj09svwAAAP//
AwBQSwMEFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAABfcmVscy8ucmVsc2zPwWrDMAwG4Ptg72B0
X5TuUMaI01uh19I+gLGVxCy2jGSy9e1nemrHjpL4P0nD4SetZiPRyNnCruvBUPYcYp4tXC/Htw8w
Wl0ObuVMFm6kcBhfX4Yzra62kC6xqGlKVgtLreUTUf1CyWnHhXKbTCzJ1VbKjMX5LzcTvvf9HuXR
gPHJNKdgQU5hB+ZyK23zHztFL6w81c5zQp6m6P9TMfB3PtPWFCczVQtB9N4U2rp2HOA44NMz4y8A
AAD//wMAUEsDBBQABgAIAAAAIQCIivqnwQAAANsAAAAPAAAAZHJzL2Rvd25yZXYueG1sRI9Bi8Iw
FITvC/6H8AQvi6YqilSjiCCIF9Ht3p/Nsy02L6WJtfrrjSB4HGbmG2axak0pGqpdYVnBcBCBIE6t
LjhTkPxt+zMQziNrLC2Tggc5WC07PwuMtb3zkZqTz0SAsItRQe59FUvp0pwMuoGtiIN3sbVBH2Sd
SV3jPcBNKUdRNJUGCw4LOVa0ySm9nm5Gwe9lkzz+9/bwnBpKJudGF+PEK9Xrtus5CE+t/4Y/7Z1W
MJrA+0v4AXL5AgAA//8DAFBLAQItABQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAAAAAAAAAAAAA
AAAAAABbQ29udGVudF9UeXBlc10ueG1sUEsBAi0AFAAGAAgAAAAhAFr0LFu/AAAAFQEAAAsAAAAA
AAAAAAAAAAAAHwEAAF9yZWxzLy5yZWxzUEsBAi0AFAAGAAgAAAAhAIiK+qfBAAAA2wAAAA8AAAAA
AAAAAAAAAAAABwIAAGRycy9kb3ducmV2LnhtbFBLBQYAAAAAAwADALcAAAD1AgAAAAA=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-size:11.0pt;
     color:black;mso-themecolor:text1;mso-font-kerning:12.0pt'>Progression free
     survival </span><span lang=EN-GB style='font-size:12.0pt'><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><v:shape id="TextBox_x0020_7" o:spid="_x0000_s1037" type="#_x0000_t202"
  style='position:absolute;top:32556;width:19011;height:5868;visibility:visible;
  mso-wrap-style:square;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQDb4fbL7gAAAIUBAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbHyQz07DMAyH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=
" filled="f" stroked="f">
  <v:textbox style='mso-fit-shape-to-text:t'>
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-size:11.0pt;
     color:black;mso-themecolor:text1;mso-font-kerning:12.0pt'>Patients at risk</span><span
     lang=EN-GB style='font-size:12.0pt'><o:p></o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-size:11.0pt;
     color:black;mso-themecolor:text1;mso-font-kerning:12.0pt'>TUC+Tras+Cape</span><span
     lang=EN-GB><o:p></o:p></span></p>
     <p class=MsoNormal><span lang=EN-GB style='mso-bidi-font-size:11.0pt;
     color:black;mso-themecolor:text1;mso-font-kerning:12.0pt'>Pbo+Tras+Cape</span><span
     lang=EN-GB><o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
 </v:shape><w:wrap type="none"/>
 <w:anchorlock/>
</v:group><![endif]--><img width="661" height="405" src="file:///C:/Users/bakhsm/AppData/Local/Temp/13/msohtmlclip1/01/clip_image004.png" /><!--[if mso & !supportInlineShapes & supportFields]><span
lang=EN-GB><v:shape id="_x0000_i1026" type="#_x0000_t75" style='width:494.3pt;
 height:302.55pt'>
 <v:imagedata croptop="-65520f" cropbottom="65520f"/>
</v:shape><span style='mso-element:field-end'></span></span><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>As planned per protocol, approximately two years after last patient randomized, the final OS analysis was performed based on 370 events, which corresponded to a median follow-up of 29.6 months. Median OS was 24.7 months (95% CI: 21.6, 28.9) for patients on the tucatinib + trastuzumab + capecitabine arm compared to 19.2 months (95% CI: 16.4, 21.4) for patients on the placebo + trastuzumab + capecitabine arm (HR = 0.725; 95% CI: 0.585, 0.898). The final OS analysis is present in Figure 3.</p><p>&nbsp;</p><p><strong>Figure&nbsp;3. Kaplan‑Meier curves of overall survival (final analysis)</strong></p><p>&nbsp;</p><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_9"
 o:spid="_x0000_s1030" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:-23.25pt;margin-top:287.15pt;width:137.55pt;
 height:49.6pt;z-index:251660288;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f"/><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Patients at risk</p><p>TUC+Tras+Cape</p><p>Pbo+Tras+Cape</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_13"
 o:spid="_x0000_s1029" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:-23.5pt;margin-top:123.5pt;width:118.4pt;height:20.2pt;
 rotation:-90;z-index:251664384;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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==
" filled="f" stroked="f">
 <v:textbox style='mso-fit-shape-to-text:t'>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal align=center style='text-align:center'><span lang=EN-GB
    style='mso-bidi-font-size:11.0pt;color:black;mso-themecolor:text1;
    mso-font-kerning:12.0pt'>Overall survival </span><span lang=EN-GB
    style='font-size:12.0pt'><o:p></o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
</v:shape><![endif]--><img width="31" height="162" alt="Text Box: Overall survival " src="file:///C:/Users/bakhsm/AppData/Local/Temp/13/msohtmlclip1/01/clip_image005.png" /><!--[if gte vml 1]><v:shape
 id="Text_x0020_Box_x0020_12" o:spid="_x0000_s1028" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:202.05pt;
 margin-top:190.4pt;width:87.4pt;height:20.2pt;z-index:251663360;visibility:visible;
 mso-wrap-style:square;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f">
 <v:textbox style='mso-fit-shape-to-text:t'/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Pbo+Tras+Cape</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_11"
 o:spid="_x0000_s1027" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:322.1pt;margin-top:139.45pt;width:149.7pt;
 height:20.2pt;z-index:251662336;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f">
 <v:textbox style='mso-fit-shape-to-text:t'/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>TUC+Tras+Cape</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_10"
 o:spid="_x0000_s1026" type="#_x0000_t202" style='position:absolute;left:0;
 text-align:left;margin-left:176.15pt;margin-top:282.75pt;width:166.6pt;
 height:17.9pt;z-index:251661312;visibility:visible;mso-wrap-style:square;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:text;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" filled="f" stroked="f"/><![endif]--></p><table cellpadding="0" cellspacing="0"><tbody><tr><td><table cellpadding="0" cellspacing="0" style="width:100%"><tbody><tr><td><p>Months since randomisation</p></td></tr></tbody></table></td></tr></tbody></table><p><!--[if gte vml 1]><v:shape
 id="Picture_x0020_30" o:spid="_x0000_i1025" type="#_x0000_t75" alt="A picture containing text, diagram, line, plot&#10;&#10;Description automatically generated"
 style='width:417pt;height:329.25pt;visibility:visible;mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/bakhsm/AppData/Local/Temp/13/msohtmlclip1/01/clip_image006.jpg"
  o:title="A picture containing text, diagram, line, plot&#10;&#10;Description automatically generated"/>
</v:shape><![endif]--><img width="556" height="439" alt="A picture containing text, diagram, line, plot

Description automatically generated" src="file:///C:/Users/bakhsm/AppData/Local/Temp/13/msohtmlclip1/01/clip_image007.jpg" /></p><p>&nbsp;</p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><u>Paediatric population</u></p><p>&nbsp;</p><p>The European Medicines Agency has waived the obligation to submit the results of studies with TUKYSA in all subsets of the paediatric population in malignant breast neoplasms (see section&nbsp;4.2 for information on paediatric use).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Plasma tucatinib exposure (AUCinf and Cmax) demonstrated dose proportional increases at oral doses from 50 to 300 mg (0.17 to 1 time the recommended dose). Tucatinib exhibited 1.7-fold accumulation for AUC and 1.5-fold accumulation for Cmax following administration of 300 mg tucatinib twice daily for 14 days. Time to steady-state was approximately 4 days.</p><p>&nbsp;</p><p><u>Absorption</u></p><p>&nbsp;</p><p>Following a single oral dose of 300 mg tucatinib, the median time to peak plasma concentration was approximately 2.0 hours (range 1.0 to 4.0 hours).</p><p>&nbsp;</p><p><em>Effects of food</em></p><p>Following administration of a single dose of tucatinib in 11 subjects after a high-fat meal (approximately 58% fat, 26% carbohydrate, and 16% protein), the mean AUCinf increased by 1.5-fold, the Tmax shifted from 1.5 hours to 4.0 hours, and Cmax was unaltered. The effect of food on the pharmacokinetics of tucatinib was not clinically meaningful, thus tucatinib may be administered without regard to food.</p><p>&nbsp;</p><p><u>Distribution</u></p><p>&nbsp;</p><p>The apparent volume of distribution of tucatinib was approximately 1670 L in healthy subjects after a single dose of 300 mg. The plasma protein binding was 97.1% at clinically relevant concentrations.</p><p>&nbsp;</p><p><u>Biotransformation</u></p><p>&nbsp;</p><p>Tucatinib is metabolized primarily by CYP2C8 and to a lesser extent via CYP3A and aldehyde oxidase.</p><p>&nbsp;</p><p><em>In Vitro drug interaction studies</em></p><p><em>&nbsp;</em></p><p>Tucatinib is a substrate of CYP2C8 and CYP3A.</p><p>Tucatinib is a reversible inhibitor of CYP2C8 and CYP3A and a time-dependent inhibitor of CYP3A, at clinically relevant concentrations.</p><p>Tucatinib has low potential to inhibit CYP1A2, CYP2B6, CYP2C9, CYP2C19, CYP2D6, and UGT1A1 at clinically relevant concentrations.</p><p>Tucatinib is a substrate of P-gp and BCRP. Tucatinib is not a substrate of OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, MATE2-K, and BSEP.</p><p>Tucatinib inhibits MATE1/MATE2-K-mediated transport of metformin and OCT2/MATE1-mediated transport of creatinine. The observed serum creatinine increase in clinical studies with tucatinib is due to inhibition of tubular secretion of creatinine via OCT2 and MATE1.</p><p>&nbsp;</p><p><u>Elimination</u></p><p>&nbsp;</p><p>Following a single oral dose of 300 mg, tucatinib is cleared from plasma with a geometric mean half- life of approximately 8.5 hours and apparent clearance of 148 L/h in healthy subjects.</p><p>&nbsp;</p><p><em>Excretion</em></p><p>Tucatinib is predominantly eliminated by the hepatobiliary route and is not appreciably renally eliminated. Following a single oral dose of 300 mg <sup>14</sup>C-tucatinib, approximately 85.8% of the total radiolabelled dose was recovered in faeces (15.9% of the administered dose as unchanged tucatinib) and 4.1% in urine with an overall total recovery of 89.9% within 312 hours post-dose. In plasma, approximately 75.6% of the plasma radioactivity was unchanged, 19% was attributed to identified metabolites, and approximately 5% was unassigned.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p>Based on population pharmacokinetic analysis according to demographic characteristics, age</p><p>(&lt;65 years (N=211); &ge; 65 years (N=27)), albumin (25.0 to 52.0 g/L), creatinine clearance (CLcr 60 to 89 mL/min (N=89); CLcr 30 to 59 mL/min (N=5)), body weight (40.7 to 138.0 kg), and race (White (N=168), Black (N=53), or Asian (N=10)) did not have a clinically meaningful effect on tucatinib exposure. There are no data for subjects with severely impaired renal function.</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>The pharmacokinetics of tucatinib have not been evaluated in a dedicated renal impairment study.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>Mild (Child&ndash;Pugh A) and moderate (Child-Pugh B) hepatic impairment had no clinically relevant effect on tucatinib exposure. Tucatinib AUCinf was increased by 1.6-fold in subjects with severe (Child-Pugh C) hepatic impairment compared to subjects with normal hepatic function. There are no data for breast cancer patients with severely impaired hepatic function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Carcinogenicity studies have not been conducted with tucatinib.</p><p>Tucatinib was not clastogenic or mutagenic in the standard battery of genotoxicity assays.</p><p>&nbsp;</p><p>In repeat-dose toxicity studies in rats, decreased corpora lutea/corpus luteum cyst, increased interstitial cells of the ovary, atrophy of the uterus, and mucification of the vagina were observed at doses of</p><p>&ge; 6 mg/kg/day administered twice daily, equivalent to 0.09 times the human exposure based on AUC0-12 at the recommended dose. No histological effects were observed on male or female reproductive tracts in cynomolgus monkeys or on male reproductive tracts in rats at doses resulting in</p><p>exposures up to 8 times (in monkey) or 13 times (in rat) the human exposure at the recommended dose based on AUC0-12.</p><p>&nbsp;</p><p>Embryo-foetal development studies were conducted in rabbits and rats. In pregnant rabbits, increased resorptions, decreased percentages of live foetuses, and skeletal, visceral, and external malformations were observed in foetuses at &ge;90 mg/kg/day; at this dose, maternal exposure is approximately equivalent to the human exposure at the recommended dose based on AUC. In pregnant rats, decreased maternal body weight and body weight gain were observed at doses of &ge;90 mg/kg/day.</p><p>Foetal effects of decreased weights and delayed ossification were observed at &ge;120 mg/kg/day; at this dose, maternal exposure is approximately 6-fold higher than human exposure at the recommended dose based on AUC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>&nbsp;</strong></p><p><u>Tablet core</u> Copovidone Crospovidone</p><p>Sodium chloride</p><p>Potassium chloride</p><p>Sodium hydrogen carbonate</p><p>Silica, colloidal anhydrous Magnesium stearate Microcrystalline cellulose</p><p>&nbsp;</p><p><u>Film-coating</u></p><p>Poly (vinyl alcohol) Titanium dioxide</p><p>Macrogol 4000</p><p>Talc</p><p>Yellow iron oxide</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30˚C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>OPA/ALU/PVC blister sealed with aluminum foil.</p><p>&nbsp;</p><p><u>TUKYSA 50&nbsp;mg film‑coated tablets</u></p><p>&nbsp;</p><p>Each carton contains 88&nbsp;film‑coated tablets.</p><p>&nbsp;</p><p><u>TUKYSA</u><u> 150&nbsp;mg film‑coated tablets </u></p><p>&nbsp;</p><p>Each carton contains 84&nbsp;film‑coated tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Keep out of the sight and reach of children.</strong></p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorization Holder:
Pfizer Europe MA EEIG
Belgium

Manufacturer:
Corden Pharma GmbH, 
Plankstadt, Germany

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2023
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>